GSTM1 and stroke disorder: A more cautious approach to excess ESA dosing has been adopted since randomized trials in CKD populations indicated an increased risk of stroke and venous thromboembolism when ESA therapy is used to target high Hb levels [22–24], especially in relatively unresponsive patients [55, 56].